Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

Status Completed

Clinical Trial Summary

The purpose of this project is to compare the efficacy (how successful) 1) standard-dose proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely blocks the stomach from producing acid) plus low dose tricyclic antidepressant (nortriptyline 50mg) (TCA); 2) double-dose PPI (rabeprazole 20 mg twice a day); to 3) standard-dose PPI (rabeprazole 20mg once daily) and placebo (an inactive substance, like a sugar pill) to determine the relative symptom resolution and health-related quality of life in gastroesophageal reflux disease (a disease characterized by a burning sensation (heartburn) behind the breast bone caused by a backflow of stomach contents into the esophagus) (GERD) patients who fail standard-dose PPI and you will be randomly assigned (similar to flipping a coin) to one of the three groups.

Clinical Trial Description

Failure of standard dose PPI to control GERD symptoms has been increasingly encountered in clinical practice (both primary care and sub-specialties) and has become one of the most challenging therapeutic dilemmas in GERD management. It has been estimated that up to 30% of the patients receiving PPI once daily will continue to report typical GERD symptoms [1]. Presently, increasing the PPI dose has been the standard of care in these patients [2]. However, success in relieving refractory GERD symptoms with such a therapeutic approach has been extremely limited, resulting in frustration of both the patient as well as the health care provided. Furthermore, patients who fail PPI will continue to seek medical attention and may undergo a variety of invasive or non-invasive tests, and thus consume already limited health care resources. Recent advancement in the understanding of the diverse composition of the different GERD groups as well as symptom generation has led to the recognition of alteration in pain perception as an important contributing factor for PPI failure in some and the presence of non-acid related stimuli in others [3].

This study will clarify for the first time the role of pain modulation in patients who failed standard dose of PPI. The clinical experience with doubling the PPI dose, which is the current standard of care, has been very limited and relatively disappointing. Additionally, this study may identify the group of PPI failure patients that may benefit from doubling the dose of PPI and the group that will benefit more from adding a pain modulator. This study is timely, has never been performed and addresses a prevalent emerging clinical dilemma in GI as well as primary care clinics. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00539240
Study type	Interventional
Source	VA Office of Research and Development
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	April 2006
Completion date	November 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02135107` - A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients	Phase 3
Completed	`NCT01432392` - Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease	N/A
Recruiting	`NCT01249482` - Symptom Assessment for GERD Patients Receiving H. Pylori Eradication	N/A
Completed	`NCT01200550` - The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients	N/A
Completed	`NCT01578642` - Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease	Phase 2
Completed	`NCT00978016` - A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)	Phase 2
Completed	`NCT00998244` - Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease	N/A
Unknown status	`NCT01128608` - The Effect of High PCO2 Solution on Esophageal Acid Sensation	N/A
Completed	`NCT00768196` - Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients	N/A
Completed	`NCT00768443` - Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)	N/A
Recruiting	`NCT00498082` - Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease	N/A
Completed	`NCT00886197` - Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease	N/A
Completed	`NCT00378898` - Feasibility of Placing Bravo PH Capsule in Proximal Esophagus	N/A
Completed	`NCT00217347` - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy	N/A
Completed	`NCT00507377` - Foreshortened Esophagus and Its Surgical Therapy
Completed	`NCT00165022` - Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population	N/A
Completed	`NCT00214552` - Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.	Phase 3
Completed	`NCT00625495` - Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)	Phase 4
Completed	`NCT00618150` - Patient Education in Gastroesophageal Reflux Disease	N/A
Completed	`NCT03299985` - Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease	N/A